HOME >> BIOLOGY >> NEWS
Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
14-Sep-2006


Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Can Gleevec help patients with rheumatoid arthritis

(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... analysis and premium industry insights on the global resorcinol industry. The report highlights ... study of vivid market scenarios and analysis of primary and secondary inputs from ...
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
Cached News: